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Mesenchymal stem cells have previously been shown to mediate brain repair after stroke; they secrete 
50–100 nm complexes called extracellular vesicles (EVs), which could be responsible for provoking 
neurovascular repair and functional recovery. EVs have been observed by electron microscopy and 
NanoSight, and they contain associated proteins such as CD81 and Alix. This purified, homogeneous 
population of EVs was administered intravenously after subcortical stroke in rats. To evaluate the EVs 
effects, we studied the biodistribution, proteomics analysis, functional evaluation, lesion size, fiber 
tract integrity, axonal sprouting and white matter repair markers. We found that a single administration 
of EVs improved functional recovery, fiber tract integrity, axonal sprouting and white matter repair 
markers in an experimental animal model of subcortical stroke. EVs were found in the animals’ brain and 
peripheral organs after euthanasia. White matter integrity was in part restored by EVs administration 
mediated by molecular repair factors implicated in axonal sprouting, tract connectivity, remyelination 
and oligodendrogenesis. These findings are associated with improved functional recovery. This novel 
role for EVs presents a new perspective in the development of biologics for brain repair.
After stroke, not only is gray matter affected, but the white matter component is also compromised1,2. Given 
the complex pathways involved in the pathogenesis of brain damage, therapies aimed at more than one cellular 
target (i.e. not only neurons, but also oligodendrocytes, axons and myelin) might prove to be more efficacious. 
Mesenchymal stem cells (MSC) were extensively investigated for their reparative properties after stroke, MSC 
participate in processes such as neurogenesis, synaptogenesis3–5, oligodendrogenesis, axonal connectivity and 
myelin formation5, showing efficacy in not only gray matter affectation, but also white matter injury. The effect of 
MSC was related to a paracrine action6. This paracrine action might include soluble factors that are secreted into 
the extracellular environment7 that modify cell behavior in a paracrine manner favoring brain recovery.
Extracellular vesicles (EVs) are small heterogeneous microvesicles, 30 to 100 nm in diameter, that store within 
themselves multivesicular bodies (DNA, RNA, proteins and lipids) and information on their various biological 
functions and their cell type-specific molecular composition. They are widely distributed in serum, urine, saliva 
and other biological fluids. As important transfer vectors for intercellular communication and genetic material, 
EVs can stimulate target exerting their biological functions8 and might be responsible for the long-distance effects 
of stem cell therapy. Specifically, EVs derived from stem cells have recently been suggested to mediate restorative 
stem cell effects9 including being an interesting source for therapeutic applications in the field of regenerative 
medicine in neural disabilities including neurodegenerative diseases9,10 and stroke7,11. In particular, EVs induce 
long-term brain protection, promote gray matter repair and neurological recovery, and modulate peripheral 
post-stroke immune response7.
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We aimed to investigate whether intravenous administration of MSC-derived EVs could induce functional 
recovery, promote oligodendrogenesis and aid white matter fiber repair when axonal tract integrity has been com-
promised, to potentially serve as a brain repair therapy after an experimental animal model of subcortical stroke.
Results
EVs characterization and biodistribution. EVs have been observed to have typical morphology and size 
(< 100 nm) by NanoSight (Fig. 1A) and electron microscopy (Fig. 1B). They contain associated proteins such as 
CD81 (a specific marker of EVs) and Alix using western blot and immunofluorescence (Fig. 1C and D).
DiI-labeled EVs were used for biodistribution and we analyzed histological sections of various organs. We 
found labeled EVs in brain tissue and in peripheral organs such as the lung, liver and spleen at 24 hours after 
administration (Fig. 1E). We also found co-labeling between DiI-labeled EVs with VEGF, NeuN, CNP-ase and 
Iba-1 at 24 hours after EVs administration (Fig. 1F and G).
Effect of EVs treatment on functional recovery.  No significant differences were found in the func-
tional outcome of the treated and control animals at 24 hours and 7 days after treatment (p > 0.05). However, 
28 days after treatment, the animals showed significantly better performance compared with the control group 
in beam walking (0.60 ± 0.699 vs. 2.60 ± 0.516, respectively; p < 0.001), the modified Rogers test (0.40 ± 0.516 
vs. 2.30 ± 0.823, respectively; p < 0.001) and the rotarod test (92.40 ± 25.881 vs. 66.70 ± 19.322, respectively; 
p = 0.022) (Fig. 2A).
Effect of EVs treatment on lesion size and tract connectivity.  MRI analysis showed that there was 
not a significant difference between groups. The lesion size was indistinguishable in the treated animals com-
pared with the control group at 7 days (15.06 ± 0.953 vs. 13.94 ± 1.364, respectively; p > 0.05). However, at 28 
days, MRI-T2 results showed a tendency to decrease the lesion size in treated animals compared to control group 
(6.013 ± 1.788 vs. 8.21 ± 0.945, respectively; p > 0.05) (Fig. 2B).
DTI tractography data showed similar results for anisotropic fractions in both the controls and the treated 
groups 7 days after different types of stroke. However, 28 days after treatment, those rats receiving EVs showed sig-
nificantly improved mean axial diffusivity compared with the control animals (170.47 ± 25.45 vs. 117.542 ± 7.255; 
p = 0.021) (Fig. 2C).
Axonal sprouting after EVs treatment. White matter of the striatum was affected after subcortical 
ischemic stroke. To determine whether EVs could enhance the axonal sprouting process, the fascicles of the axons 
projecting from the overlying cortex were retrogradely labeled.
To make a baseline measurement of the severity of damage, CTB tracer was injected at the lesion site. 
CTB-labeled neurons were present in overlying cortical areas ipsilateral and contralateral to the stroke site. There 
was no difference in the severity of induced stroke between the treated and control animals, indicating that the 
white matter injury was similar in both (p > 0.05) (Fig. 2D).
Once we found that the severity of damage in white matter tracts was the same in both groups, axonal sprout-
ing was studied using an anterograde neuronal tracer with BDA injected into the cortex. Three weeks after stroke, 
BDA was injected into the forelimb motor cortex because cortical projections have an important role in motor 
function and movement. Striatal axonal density was studied 1 week after the injection. A statistically signifi-
cant number of BDA-labeled axons were shown in the striatum of the treated group compared with the control 
animals (367.91 ± 65.87 vs. 86.12 ± 21.17, respectively; p < 0.05). Moreover, we observed an increase of axonal 
density in the cortex area by anterograde BDA tracer in the treated group (791.32 ± 69.14 vs. 1456.32 ± 57.24, 
respectively; p < 0.05) (Fig. 2D). These results might indicate that EVs treatment produces significant axonal 
sprouting from the cortex to the striatum.
Effect of EVs treatment on oligodendrocyte -associated markers expression.  Levels of markers 
related to the first steps of oligodendrocyte progenitor cell (OPC) development were analyzed in the lesion area 7 
days after treatment (Fig. 3). CNP-ase appears to be one of the earliest events of oligodendrocyte differentiation. 
Notably, using western blot analysis, there was a significant increase in CNP-ase marker levels in EVs-treated 
animals compared with the control animals at 7 days after treatment (1.132 ± 0.177 vs. 0.865 ± 0.034, respec-
tively; p = 0.05). (Fig. 3B and C). A2B5 is a cell surface ganglioside epitope expressed in OPCs, and its levels were 
higher in the EVs-treated animals compared with the control group at 7 days after treatment (1.807 ± 0.482 vs. 
0.774 ± 0.045, respectively; p = 0.023) (Fig. 3B and C).
A marker related to later developmental steps in mature oligodendrocytes (MOG) was also analyzed at 28 
days after treatment. After western blot analysis, there were significantly higher MOG levels in the animals that 
received EVs compared with the control group (1.650 ± 0.226 vs. 0.854 ± 0.167, respectively; p = 0.02) (Fig. 3B 
and C). All these results were confirmed by immunofluorescence analysis (Fig. 3A and C).
Myelin restoration. Study of myelin fiber morphology identified the lesion zone in all the animals as a sub-
cortical infarct affecting the white matter, with more myelinated axons in the EVs-treated animals compared with 
the control group (249.43 ± 3.90 vs. 204.78 ± 21.13, respectively; p = 0.032) (Fig. 3D and E).
Proteomic analysis of the EVs. Proteomics analysis of the EVs identified 2416 proteins (Fig. 4) that are 
implicated in three different global functions such as molecular function regulator, catalytic activity and bind-
ing. All functions in detail are shown in Fig. 4A. The majority of the EVs-contained proteins are involved in 
hydrolase activity, tubulin binding, protein kinase regulator activity, kinase regulator activity and catalytic activity 
(Fig. 4B). Interestingly, the processes in which are implicated the proteins are cellular metabolic process, nucleic 
acid metabolic process, regulation of smooth muscle contraction, cofactor biosynthetic process, inorganic ion 
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transmembrane transport, RNA metabolic process, coenzyme biosynthetic process, apoptotic process, B cell acti-
vation, cellular modified amino acid biosynthetic process, DNA recombination, polarized epithelial cell differen-
tiation, establishment of epithelial cell apical/basal polarity and establishment of epithelial cell polarity (Fig. 4C).
Figure 1. EVs characterization and biodistribution. EVs were characterized using various techniques 
(A) Histogram representing a distribution graph on a particle-by-particle (events) and size of the EVs 
using NanoSight (left), EVs image by NanoSight (right) (B) EVs image by electronic microscope, (C) 
immunoflorescence and (D) western blot. The gel image was cropped. (E) EVs (red) were found 24 hours after 
i.v. infusion in the brain, lung, liver and spleen by immunofluorescence. (F) DiI colocalization (representated 
by arrows) was shown with VEGF, NeuN, CNP-ase and Iba-1 in brain samples. White stroked line has been 
used to indicate the specific longitudinal section where the fluorescence intensity has been studied and 
represented in (G). (G) Quantification of fluorescence intensity of each marker found in the longitudinal profile 
of pixel of the white stroked line (n = 4 animals per group). Abbreviations: CNP-ase, 2′ ,3′ -Cyclic-nucleotide 3′ 
-phosphodiesterase; DAPI, 4′ ,6-diamidino-2-phenylindole; Iba-1, ionized calcium-binding adapter molecule 1; 
NeuN, Neuronal Nuclei; VEGF, vascular endothelial growth factor.
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Figure 2. Improved functional outcome reduced infarct size and increased fiber tract and axonal 
sprouting after EVs treatment in subcortical stroke. (A) Beam walking test performance (left), the Rogers 
test (middle) and the Rotarod (right) was improved at 28 days (p < 0.05) in the treatment group compared with 
the controls (p < 0.05) (Data are shown as mean ± SEM, *p < 0.05; n = 10 animals per group). (B) Comparative 
image analysis of T2-weighted MRI at 7 and 28 days. (C) Comparative image analysis of tractography. 
Detail of tractography image in the lesion is given below at 28 days. Quantitative analysis of MRI images and 
tractography (data are shown as mean ± SEM, *p < 0.05, n = 4 animals). (D) Representative photomicrographs 
of cortical neuronal projections through the stroke site labeled with the anatomical tracer cholera toxin subunit 
B (CTB). Photomicrographs of cortical cells previously labeled with BDA and striatal axons from cortical cells 
labeled with biotinylated dextran amine (BDA). Quantification of cortical cells labeled with CTB that project to 
striatum (left), cortical cells labeled with BDA (middle) and striatal axons that have been projected from cortical 
cells labeled with BDA (right). (Data are shown as mean ± SEM, *p < 0.05, n = 4 animals). Abbreviations: BDA, 
biotin dextran amine; CTB, Cholera Toxin Subunit B.
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Figure 3. White matter-associated markers are enhanced after EVs therapy in subcortical stroke model (A) 
Immunofluorescence images of white matter repair-associated markers (CNP-ase, A2B5 and MOG).  
(B) Western blot images. The gels image was cropped. (C) Western blot and IF quantification of white matter 
repair-associated markers. (D) Morphological study by CryoMyelin staining identified the zone of the lesion 
as an area of white matter injury located in the subcortical zone, showing restored myelinated axons in the 
exosome-treated. Yellow line indicates a representative longitudinal profile of pixel intensity. (E) Quantification 
of the quantity of white colour in the along to the yellow line and quantification of mean ROI intensity of the 
CryoMyelin staining. (Data are shown as mean ± SEM, scale bars = 20 μm, *p < 0.05, n = 4 animals,  
5 sections each per group). Abbreviations: CNP-ase, 2′,3′-Cyclic-nucleotide 3′-phosphodiesterase; MOG, 
Myelin Oligodendrocyte Glycoprotein.
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Discussion
The present study has demonstrated that a single administration of EVs is a therapeutic strategy to repair white 
matter damage after subcortical ischemic stroke. After intravenous infusion, EVs were found in the brain and 
in the peripheral organs (liver, lung and spleen). After EVs treatment, the animals showed improved functional 
recovery and increased axonal sprouting, oligodendrocyte-associated marker expression and myelin formation, 
white matter thickness (width, breadth, depth) and restoration of tract connectivity at 28 days. Proteomics anal-
ysis of the EVs identified 2416 proteins that are implicated in brain repair function.
The high frequency of white matter damage motivates the study of axonal sprouting and growth, oligoden-
drocyte formation, tract connectivity and remyelination because all are necessary for brain repair processes to 
improve functional and cognitive deficits after stroke. Several studies demonstrated that the administration of 
MSC improved functional deficits after various experimental models of stroke12,13. These beneficial effects were 
shown to be associated with a transient recruitment of MSC within the peripheral organs4,5. Based on this obser-
vation, it has been suggested that MSC might provide paracrine support for brain repair14.
EVs, are small vesicles released by cells bearing the surface antigen characteristic of the cell of origin. EVs 
might enter the target cells through specific receptor-ligand interactions and might deliver selected patterns of 
transferring receptors, proteins and bioactive lipids9. Thus, EVs could act as bioreactors, which could partially 
explain the paracrine effects observed in stem cell-based therapeutic approaches, and they can play a beneficial 
role in restoring tissue and organ damage. In the present study, EVs were found in both intracellular and extracel-
lular compartments not only in the brain (area of injury) but also in various peripheral organs such as the lung, 
liver and spleen at 24 hours after treatment.
EVs purified from different cells have garnered tremendous interest based on the capacity of enhance repair 
in various pathologies of acute myocardial infarction15, chronic heart failure, spinal cord injury, stroke, wound 
healing16, cutaneous wound healing17 and proliferation of intestinal endothelial cells18. Even, EVs can act as an 
immune system regulatory tool19. The present study extends the effect of MSC-derived EVs to a model of subcor-
tical ischemic stroke. In this model, EVs were used as a treatment to enhance white matter repair. Some studies 
have reported that GFP-tagged EVs enriched extracellular particles were released from MSC that were intrave-
nously administered to rats with stroke and transferred to adjacent astrocytes and neurons20.
In a translational study it is important to analyze whether EVs treatment acts on the motor dysfunctions 
that are characteristic of subcortical stroke. In this study, EVs treatment induced a significant improvement in 
functional recovery that was particularly notable at 28 days after treatment compared with controls. These results 
clearly suggest a true recovery-enhancing effect from EVs. Although no previous studies have administered EVs 
in a subcortical stroke model, our results are consistent with previous data which demonstrated that systemic 
administration of MSC-generated EVs significantly improved functional recovery in other experimental animal 
model of stroke (ischemia) and traumatic brain injury11,21.
Recent studies demonstrate that intravenous administration of cell-free MSC-generated EVs enhances neu-
rovascular plasticity and neurite remodeling in rats after stroke22. A subcortical stroke animal model was chosen 
to determine whether EVs treatment could enhance axonal sprouting and tract connectivity, given the region 
of the subcortical white matter contains fascicles of axons projecting from the overlying motor cortex. Neurons 
Figure 4. Proteomics analysis of ADMSC secretome reveals multiple biological functions (A) Gene ontology 
(GO) analysis of the 2,416 proteins identified by Orbitrab proteomic study. (B) Number of proteins associated 
with each biological function. (C) Processes in which are implicated proteins.
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were labeled in an anterograde manner by a BDA injection into the cortex 3 weeks after stroke in order to map the 
connections growing after EVs treatment. A higher number of BDA-labeled axons were shown of the striatum in 
the treated group compared with the control animals. These results might indicate that EVs treatment produces 
a significant axonal sprouting response from the ipsilateral cortex to the injured striatum. All these results agree 
with those obtained by DTI tractography. This technique showed that fiber tract integrity and tract thickness 
was recovered at 28 days following EVs administration. These results suggest that good functional recovery at 
28 days could be related to axonal sprouting white matter thickness (width, breadth, depth) and restoration of 
tract connectivity in the EVs-treated animals. For this reason, EVs administration could be involved in the pro-
cess by which restructured axons, which had previously been compromised and demyelinated, recover not only 
their proper structure but also tract connectivity. These results are consistent with previous data showing neurite 
remodeling in the cortical ischemic boundary zone after other type of stroke22. Although there are no previous 
studies that study the effects of administered EVs in axonal sprouting after stroke, our results are complemented 
with previous data which demonstrated that EVs significantly increased the number of newborn mature neurons 
in the dentate gyrus after another type of neurology disease, traumatic brain injury23.
In this study, focal injection of the vasoconstrictor ET-1 into the subcortical white matter produced a visible 
infarct on MRI, as previously shown in subcortical stroke studies24,25. To analyze whether the EVs effect could 
be visualized with in vivo imaging techniques, we acquired T2-MRI maps. No significant differences in lesion 
size were observed in the EVs-treated animals compared with the control group on the T2-MRI images. These 
results agree with other studies that showed EVs-treatment did not reduce lesion size but significantly improved 
functional recovery after other type of neurological disease, traumatic brain injury23. Thus, the relationship, if any, 
between the lesion size and axonal sprouting and tract connectivity remained unclear. Thus we intensified the 
histological analysis of the injured tissue in this study.
For a correct brain repair process, not only axons, but also oligodendrocytes and myelin formation are impor-
tant. In this study, we measured oligodendrocyte-associated markers in both the treated and the control ani-
mals to determine whether EVs administration also acts on oligodendrocytes and shattered white matter fibers. 
Related to the first steps in the genesis and migration of OPC, markers such as A2B5 (a characteristic OPC 
marker)26 and CNP-ase (markers related to earliest events in oligodendrocyte differentiation)27, were studied in 
the lesion area at 7 days after treatment. Markers related to white matter differentiation and myelin fiber matura-
tion such as MOG were analyzed at 28 days.
In our study, the levels of the A2B5 and CNP-ase markers at 7 days and MOG at 28 days were higher in the 
cell-free EVs-treated animals. Although there have been no previous studies examining the effects of adminis-
tered EVs in oligodendrocyte formation, our results are complemented with previous data that demonstrated 
systemic administration of EVs significantly reduced astrocytic GFAP expression and alleviated the expression of 
NeuN positive neurons after stroke in mice28.
Furthermore, in the process of white matter repair, the myelin sheath, which allows the transmission of nerve 
impulses over relatively long distances, is necessary for whole brain function. A cryomyelin study showed an 
increase of myelin in EVs-treated animals compared with the control group. These results could indicate that 
newly generated axons could themselves be covered by myelin.
In order to elucidate the mechanisms underlying all these repair processes the components of the EVs pro-
teome need to be identified. Our proteomics analysis identified 2416 proteins; which are associated with several 
functions such as hydrolase activity, tubulin binding, protein kinase regulator activity, kinase regulator activity 
and catalytic activity. These results agree with other studies that revealed that secretome from MSC is related to 
protein binding and metabolic function5. Interestingly growth factor activity was not the main represented func-
tion in the cell secretome, indicating that other functions are also relevant. Our findings suggest that the identified 
proteins could contribute to improve functional recovery after EVs administration. When the specific molecules 
necessary for a therapeutic effect are known, selective manipulation of expression of those molecules might lead 
to an enhancement of the therapeutic efficiency of isolated EVs.
Conclusions
In conclusion, our study helped us identify a clear role for EVs derived from MSC in improving functional out-
come by mediating axonal sprouting and growth, oligodendrocyte formation, tract connectivity and remyelina-
tion after subcortical ischemic stroke. In the current study, EVs derived from MSC were found not only in the 
brain, but also in the peripheral organs, such as the lung, liver and spleen. Proteomic analyses identified 2416 
proteins, some of which are associated with several regulation functions.
Methods
Ethics Statement. In this study, animal care and experimental procedures were strictly in accordance with 
the Guide for the Care and Use of Laboratory Animals, and approved by the Institutional medical school’s Ethical 
Committee for the Care and Use of Animals in Research of the La Paz University Hospital, according to the 
Spanish and European Union (EU) rules (86/609/CEE and RD53/2013). Experiments were reported according to 
all stroke therapy academic industry roundtable29 and RIGOR30 guidelines in terms of randomization, blinding 
and statistical powering.
Animals and Surgery. The subcortical infarct (SCI) model has been well established5,25. Male 
Sprague-Dawley rats (200–250 g) were anesthetized using 3.5% isoflurane in 2 L/min oxygen and given meloxicam 
2 mg/kg for analgesia. Subcortical stroke was induced by injection of 1 μ L of endothelin-1 (ET-1; Calbiochem) 
(0.25 μ g/μ L) with the use of a SYR 5 uL Hamilton (Tecknokroma) into the striatum using stereotactic references 
(+ 0.4 mm AP, + 3.5 mm L, + 6 mm DV from bregma)
www.nature.com/scientificreports/
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A total of 54 male Sprague-Dawley rats (8–9 weeks old, weighing 200–250 g) were used in this study. The study 
groups were as follows: (I) sham operation group (n = 10); (II) SCI control: SCI + 1 ml i.v. saline (n = 20); (III) 
SCI-treated: SCI + 100 μ g i.v. EVs (n = 20) (Fig. 5). Additionally, 4 animals were used for biodistribution analysis, 
which were euthanized at 24 hours after treatment.
Treatment was administered by the tail vein at 24 hours after surgery. The rats were euthanized at 7 days or at 
28 days (n = 10/each). One rat was excluded from the study because it died after stroke surgery.
Cell culture protocol, isolation and EVs characterization. MSC obtained from allogeneic adipose 
tissue of Sprague-Dawley rats (250–300 g) were cultured. The adipose tissue was digested with collagenase (Sigma 
Aldrich) and incubated at 37 °C in 5% CO2. On the third pass, the cell cultures were characterized (CD90+ /
CD29+ /CD45− /CD11b- cells) using a FACScalibur cytometer and CellQuest Pro software (Becton Dickinson). 
MSC for EVs isolation were cultured overnight with a free exosome-FBS culture medium. After 24 hours, cell 
supernatants were collected and the EVs were extracted using an exosome extraction kit (miRCURYTM Exosome 
Isolation Kit, EXIQON), following the manufacturer’s instructions. EVs were used for treatment, for biodistri-
bution study and for proteomic analysis and have been observed by electron microscopy and NanoSight. They 
contain associated proteins, such as CD81 and Alix using western blot and immunofluorescence.
Biodistribution of EVs. The EVs were labeled with DiI (Celltracker CM-DiI, Invitrogen) prior to 
administration. Cryosections (40 μ m thick) of lung, liver, spleen and brain were counterstained with 4′ , 
6-diamidino-2-phenylindole (DAPI), and the biodistribution was analyzed by immunofluorescence staining at 
24 hours.
In order to characterize which cell type contains the EVs administered to the brain, we co-stained with 
DiI-labeled EVs and VEGF (1:500, Millipore), NeuN (1:100, Millipore), CNP-ase (1:500, Sigma-Aldrich) and 
Iba-1 (1:1000, Millipore), followed by the goat anti-mouse and anti-rabbit Alexa Fluor 488 antibody (1:750, 
Invitrogen). Images were acquired as a confocal maximum projection using a Leica TCS-SPE confocal micro-
scope (Leica) and the number of double-positive cells was counted in a minimum of 6 different microscopic fields 
using a 40× objective lens and Image-ProPlus 4.1 software.
Functional evaluation scales. Functional evaluation was performed for all animals by a blinded observer 
before surgery and after 48 hours, 7 days and 28 days. Motor performance was evaluated using the beam walking, 
Rogers and rotarod test. The beam walking test measured the ability of the rats to walk along a wooden beam 
(2.5 × 2.5 × 80 cm)25. The rotarod test measured the latency to fall from a rotating cylinder5. A variant of Rogers’ 
functional scale was used to assign scores31.
In vivo magnetic resonance imaging (MRI).  Lesion size was analyzed after 7 and 28 days by MRI using 
a 7-Tesla horizontal bore magnet (Bruker Pharmascan, Ettlingen, Germany) and a T2-weight spin eco image. For 
this procedure, animals were anesthetized with a 2% isoflurante-oxygen mixture in an induction chamber and 
the flow of anesthetic gas was constantly regulated to maintain a breathing rate of 50 + /− 20 bpm. The lesion area 
Figure 5. Experimental protocol schematic. EVs were isolated from rat adipose tissue-derived MSC and 
subsequently characterized. Male rats were injected with endothelin-1 to induce subcortical ischemic stroke. 
During the same surgery, half the animals were inoculated with CTB as Retrograde tracer. Twenty-four 
hours post stroke, treatment (saline or exosome) was administered through the tail vein. Later, 24 hours 
after treatment and on day 7, behavior and imaging and histological studies were evaluated. The other half 
of the animals were injected with BDA as anterograde tracer 21 days after treatment. Functional evaluation 
was studied at 48 hours, 7 and 28 days after treatment. These groups of animals were euthanized at 28 days. 
Abbreviations: BDA: biotin dextran amine; CTB, Cholera Toxin Subunit B; FE, Functional evaluation; MRI, 
Magnetic Resonance Image.
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was expressed as a percentage of the contralateral hemisphere, after correcting for brain edema. For tractography 
analysis, diffusion-weighted magnetic resonance images were acquired at 7 and 28 days after stroke. Diffusion 
tensor data were acquired with a spin echo single shot echo planar imaging (EPI) pulse sequence using the fol-
lowing parameters: TR/TE 8000/35 ms; a signal average of 12, 30 noncollinear diffusion gradient scheme with a 
diffusion weighting b = 500 s/mm2 and b = 1000 s/mm2, 18 slices with a slice thicknesof 1.5 mm without a gap, 
field of view 35 × 35 mm. Total imaging time was 1 h 44 min. All EPI data were acquired with a single shot EPI 
sequence, 96 × 96 matrix, and zero filled in k space to construct a 128 × 128 image matrix. Fractional anisotropy, 
mean diffusivity, trace, the eigenvalues and eigenvector maps were calculated with a homemade software appli-
cation written in Matlab (R2007a) and the 3D fiber tract map was created using the MedINRIA DTI Track soft-
ware (http://www-sop.inia.fr/asclepios/software/MedINRIA). Zoomed lesion site 3-dimensional diffusion tensor 
images were represented using ParaView 4.1.0 software as previously described24.
Mapping of Motor Cortex Connections. An intracortical injection of 0.5 ul anterograde neuronal tracer 
biotinylated dextran amine ([BDA] 10.000 molecular weight, Life Technologies, Grand Island, NY, USA) was used 
to asses axonal sprouting after treatment using the following coordinates (x = 0.04; y = 0.35; z = 1.6). BDA was 
injected into the motor cortex of the rats at 3 weeks post treatment. The rats were euthanized 1 week after BDA 
injection. All the brains were stained with Cy-5-conjugated streptavidin (Jackson ImmunoResearch, West Grove, 
PA, USA). A DMLB epifluorescent microscope (Leica Microsystems) was used to observe sections under the Cy3 
filter. The BDA cortical cells were quantified using neuroanatomical quantification software (StereoInvestigator, 
MBF Bioscience). Ipsilateral and contralateral axons of the striatum and cortex were studied32,33.
A retrograde neuronal tracer cholera toxin Subunit B (CTB) (Cy3-labeled CTb, List Biological Laboratories, 
Campbell, CA, USA, diluted to 20 mg/mL in 10% DMSO) was also used to analyze changes in axonal sprouting 
after treatment. For mapping of CTB axons, 0.5 uL of CTB (diluted to 20 mg/mL in 10% DMSO) was infused 
with endothelin-1. The animals were euthanized 7 days after treatment. Sections were mounted, cover slipped 
and visualized under the Cy3 filter on a DMLB epifluorescent microscope (Leica Microsystems). Cortical cells 
labeled with CTB were quantified using neuroanatomical quantification software (StereoInvestigator, MBF 
Bioscience)32,33.
Immunohistochemistry, immunofluorescence and western blot analyses.  Frozen sections were 
stained using the CryoMyelin Kit (Hitobiotech), which allows sensitive localization and visualization of myelin 
fibers. The mean intensity of myelin staining in the region of interest was quantified using a Nikon Eclipse-Ti 
inverted microscope and NIS-elements software. The lesion area was studied in detail using immunofluorescence 
and western blot analyses. The various antibodies used for these analyses were CNP-ase (1:500, Sigma-Aldrich), 
A2B5 (1:500, Millipore) and MOG (1:100, Abcam), followed by goat anti-mouse and anti-rabbit Alexa Fluor 488 
(1:750, Invitrogen). For western blot analysis, the units were normalized based on Β -actin (1:400, Sigma-Aldrich). 
To quantify the expression of white matter-associated markers, the mean fluorescence intensity was evaluated 
using a 40× objective lens. The experiments, images and quantification of the samples were performed by blinded 
observers, using the same microscope configurations to eliminate bias due to background normalization (4 ani-
mals from each group).
Proteomics data analysis. For proteomic analysis of exosome content, proteins were digested using the 
filter-aided sample preparation (FASP) protocol34. Briefly, samples were dissolved in 50 mM Tris-HCl (pH 8.5), 
4% SDS and 50 mM DTT, boiled for 10 min and centrifuged. Protein concentration in the supernatant was meas-
ured by the Direct Detect® Spectrometer (Millipore). Approximately 50 μ g of protein was diluted in 8 M urea in 
0.1 M Tris-HCl (pH 8.5) (UA), and loaded onto 30 kDa centrifugal filter devices (FASP Protein Digestion Kit, 
Expedeon, TN, USA). The denaturation buffer was replaced by washing 3 times with UA. The proteins were 
later alkylated using 50 mM iodoacetamide in UA for 20 min in the dark, and the excess alkylation reagents were 
eliminated by washing 3 times with UA and 3 additional times with 50 mM ammonium bicarbonate. Proteins 
were digested overnight at 37 °C with modified trypsin (Promega, Madison, WI, USA) in 50 mM ammonium 
bicarbonate at a 40:1 protein:trypsin (w/w) ratio. The resulting peptides were eluted by centrifugation with 50 mM 
ammonium bicarbonate (twice) and 0.5 M sodium chloride. Trifluoroacetic acid (TFA) was added to a final con-
centration of 1% and the peptides were finally desalted onto C18 Oasis-HLB cartridges and dried-down for fur-
ther analysis.
Peptides were loaded into the LC-MS/MS system for online desalting onto C18 cartridges and analyzing by 
LC-MS/MS using a C-18 reversed phase nano-column (75 μ m I.D. × 50 cm, 2 μ m particle size, Acclaim PepMap 
RSLC, 100 C18; Thermo Fisher Scientific, Waltham, MA, USA) in a continuous acetonitrile gradient consisting 
of 0–30% B in 180 min, 50–90% B in 3 min (A = 0.5% formic acid; B = 90% acetonitrile, 0.5% formic acid). A 
flow rate of 200 nL/min was used to elute peptides from the RP nano-column to an emitter nanospray needle for 
real-time ionization and peptide fragmentation on an Orbitrap Elite mass spectrometer (Thermo Fisher). An 
enhanced FT-resolution spectrum (resolution = 35000), followed by the MS/MS spectra from the most intense 
15 parent ions were analyzed along the chromatographic run. Dynamic exclusion was set at 30 s.
For peptide identification, all the spectra were analyzed with Proteome Discoverer (version 1.4.0.29, Thermo 
Fisher Scientific) using SEQUEST-HT (Thermo Fisher Scientific). For database searching at the Uniprot database, 
parameters were selected as follows: trypsin digestion with 2 maximum missed cleavage sites, precursor and 
fragment mass tolerances of 600 ppm and 0.02 Da, respectively, carbamidomethyl cysteine as fixed modification 
and methionine oxidation as dynamic modifications. Peptide identification was validated using the probability 
ratio method34 with an additional filtering for precursor mass tolerance of 10 ppm. The false discovery rate (FDR) 
was calculated using inverted databases and the refined method35. For the study of the biological functions of 
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identified proteins, gene onthology analysis was performed using the GOrilla (Gene Ontology enRIchment anaL-
ysis and visuaLizAtion) research tool36.
Statistical analysis. Results were expressed as mean ± standard error (S.E.M.). Data were compared using 
the Kruskal-Wallis test followed by the Mann-Whitney test. Values of p < 0.05 were considered significant at a 
95% confidence interval; the data were calculated using statistical SPSS 16 and GraphPad software.
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